Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Alkermes plc
  • Anthera Pharmaceuticals Inc.
  • BIND Therapeutics Inc.
  • Celgene Corp.
  • Celldex Therapeutics
  • Cerus Corp.
  • Coronado Biosciences
  • CytoSorbents Corp.
  • Incyte Corp.
  • Isis Pharmaceuticals Inc.
  • Johnson & Johnson
  • Novavax Inc.
  • Omeros Corp.
  • OncoGenex Pharmaceuticals Inc.
  • Pharmacyclics Inc.
  • Sangamo BioSciences Inc.
  • The Medicines Company
  • Verastem Inc.

John McCamant

Medical Technology Stock Letter

Image: John McCamant

John McCamant is the editor of the Medical Technology Stock Letter, a leading investment newsletter. McCamant has spent 25 years on the frontlines of biotechnology investing. He has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Reuters, Bloomberg, CBS and Marketwatch.

The Medical Technology Stock Letter has earned the #1 ranking from Hulbert's Financial Digest. >Read More




Recent Interviews

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust (1/15/14) stethbillfold82142013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.

John McCamant Scans Under the Radar for Promising Biotechs (9/26/13) With more than 25 years of experience in the biotech market, John McCamant, editor of the Medical Technology Stock Letter, understands how the seasons of the investment cycle can influence a company's value. But he sticks to the fundamentals: After all, a great pipeline and competent management can propel a biotech upward through blustery weather as well as blue sky. Find out how four companies fit his philosophy in this interview with The Life Sciences Report.

Six Superstars for Your Biotech Portfolio: John McCamant (5/9/13) We are in the "golden age," of biotech, and Medical Technology Stock Letter Editor John McCamant has innovative ideas on how to glean profits from the renaissance. Investors should be looking at companies with excellent management and platform technologies that offer multiple opportunities for success. McCamant names his favorites in this interview with The Life Sciences Report, including one company with a radical therapy that harkens back to the days before the reign of hand sanitizer.

Recent Quotes

"We continue to believe that OGXI is undervalued." (12/21/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"The potential of CYCC's phase 3 trial with AML gives the Street more confidence." (10/25/12) Cyclacel Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >

"If OGXI-011 starts delivering in phase 3, OGXI could be a five- or tenbagger." (10/4/12) OncoGenex Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >

"We continue to believe that OGXI is undervalued." (7/20/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"Data from OGXI's phase 2 trial for OGX-427 is encouraging." (6/8/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"We are pleased OGXI is flexible in its OGX-011 development plans." (3/16/12) OncoGenex Pharmaceuticals Inc. - John McCamant, Medical Technology Stock Letter More >

"OGXI could be a home-run stock." (2/23/12) OncoGenex Pharmaceuticals Inc. - The Life Sciences Report Interview with John McCamant More >



Due to permission requirements, not all quotes are shown.